휴마시스
Financials
Valuation Metrics
휴마시스's Market Cap is ₩547B. At end of 2025 it was ₩1251B. Ranked #1676 of 2,436 in KR market (top 69%), #1003 of 1,649 on KOSDAQ (top 61%), #68 of 96 in Health Care Equipment & Services (top 71%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 54.66B KRW | KR#1,676/2,436 Sec#68/96 |
| Revenue | 32.87B KRW | KR#1,996/2,436 Sec#62/96 |
| Net Income | -15.50B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 326.18B KRW | KR#969/2,436 Sec#21/96 |
| Net Assets | 235.48B KRW | KR#837/2,436 Sec#20/96 |
| Employees | 69 | KR#1,867/2,436 Sec#74/96 |
| Value | ||
| P/B | 0.23x | KR#178/2,436 Sec#1/96 |
| P/S | 1.66x | KR#1,728/2,436 Sec#44/96 |
| Profitability | ||
| ROE | -6.58% | KR#1,794/2,436 Sec#59/96 |
| ROA | -4.75% | KR#1,881/2,436 Sec#62/96 |
| Op. Margin | -28.74% | KR#2,175/2,436 Sec#73/96 |
| Revenue Growth | 44.76% | KR#335/2,436 Sec#12/96 |
| Financial Health | ||
| Debt Ratio | 138.51% | KR#1,009/2,436 Sec#48/96 |
| Total Debt | 13.19B KRW | KR#1,523/2,436 Sec#46/96 |
| Cash | 12.55B KRW | KR#1,534/2,436 Sec#53/96 |
| Current Ratio | 2.29x | KR#821/2,436 Sec#44/96 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -68.01% | KR#2,325/2,436 Sec#92/96 |
| 1M Return | -3.90% | KR#1,294/2,436 Sec#57/96 |
| From 52W High | -70.78% | KR#2,162/2,436 Sec#80/96 |
| 1Y MDD | -74.00% | KR#2,101/2,436 Sec#78/96 |
| Trading | ||
| Volume | 32,712 shares | KR#1,601/2,436 Sec#70/96 |
| Foreign Own. | 6.95% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -403 KRW | KR—/2,436 Sec—/96 |
| BPS | 9,612 KRW | KR#967/2,436 Sec#20/96 |
Company Info
Humasis, established in 2000 as a manufacturer of in-vitro diagnostic medical devices, was listed on the KOSDAQ market in 2017 after merging with HI No. 2 Special Purpose Acquisition Company. The company specializes in the development and production of POCT immunoassay reagent product lines. Through its subsidiary, Billionths, Humasis also manufactures condoms and medical rubber products and operates an entertainment business. It is pursuing business diversification by obtaining approval for new objectives like mineral development and sales at its 2024 regular general meeting of shareholders and is headquartered in Anyang-si, Gyeonggi-do.